Iambic Therapeutics files for US IPO with Nvidia backing

Nvidia: Nvidia is a technology company known for its graphics processing units and AI computing infrastructure that powers machine learning applications. It serves as both an investor and technology collaborator in Iambic Therapeutics, supporting optimization of the biotech's AI models on Nvidia hardware and software. The company's role underscores expanding use of advanced AI computing across life sciences and drug discovery. Iambic Therapeutics: Iambic Therapeutics is a clinical-stage biotechnology company based in San Diego that applies artificial intelligence through its molecular superintelligence platform to discover and develop novel small-molecule therapies. The company maintains technology and discovery partnerships with pharmaceutical firms including AbbVie, Takeda, and others to extend its platform across oncology, immunology, neuroscience, and additional therapeutic areas. It filed for a US IPO to support advancement of its early-stage cancer drug pipeline. IPO Activity: Iambic's filing contributes to an active period of biotech company listings on US exchanges this fall. AI Collaborations: Iambic simultaneously announced a multi-year partnership with AbbVie to apply its AI platform for discovering small-molecule therapies in immunology, neuroscience, and oncology.